ZYUS Life Sciences Corporation

As of June 30, 2026, ZYUS Life Sciences Corporation carries a market capitalization of 39.86M, placing it among publicly traded companies globally. Its enterprise value stands at 63.49M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

ZYUS Life Sciences Corporation's next confirmed earnings release is scheduled for November 26, 2026.

As of June 30, 2026, ZYUS Life Sciences Corporation has 80.52M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 105.44, and the price-to-book ratio stands at -1.48.

These figures are as of June 30, 2026. The EV/Sales ratio of 169.77 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 63.49M versus a market cap of 39.86M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, ZYUS Life Sciences Corporation maintains a current ratio of 0.04, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -88.40, indicating conservative leverage, while an interest coverage ratio of -4.45 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -239.03, reflecting losses generated across the asset base. Inventory turnover of 1.00 indicates how many times ZYUS Life Sciences Corporation sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 19, 2026, ZYUS Life Sciences Corporation's stock has declined approximately 26.47% over the past 52 weeks. The 50-day moving average sits at 0.56, while the 200-day moving average is 0.65.

Over the twelve months ended June 30, 2026, ZYUS Life Sciences Corporation generated 374,000.00 in revenue and converted that into -19.46M in net income, yielding earnings per share of -0.24. EBITDA reached -14.34M, while operating income came in at -11.31M.

As of June 30, 2026, ZYUS Life Sciences Corporation holds 202,000.00 in cash and equivalents against 23.84M in total debt, resulting in a net debt position of 21.64M. Total book value stands at -26.96M, with working capital of -21.89M providing operational flexibility.

ZYUS Life Sciences Corporation produced -7.10M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -11,000.00 in capital expenditures, free cash flow totaled -7.11M - equivalent to -0.09 per share.

Over the twelve months ended June 30, 2026, ZYUS Life Sciences Corporation posted a gross margin of 1.34, reflecting its pricing power and cost economics. The operating margin of -3,022.99 and net profit margin of -5,202.41 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -18.02: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -16.93, meaning ZYUS Life Sciences Corporation raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, ZYUS Life Sciences Corporation has an Altman Z-Score of -76.11, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.